| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 162.32 | 3.5% | 8.3% |
| Total Income | 162.32 | 3.5% | 8.3% |
| Expenditure | 152.85 | 23.1% | 12.7% |
| PBT | 2.92 | 107.1% | 99.8% |
| Net Profit | 14.07 | 127.1% | 98.8% |
| OPM | 5.84% | 23.93pp | 17.56pp |
| NPM | 8.67% | 39.57pp | 91.33pp |
| EPS | 1.41 | 127.1% | 90.5% |
WW International Announces Q2 2026 Results
06 Aug 2026 · 6 Aug, 1:44 am
Summary
WW International announced its second quarter 2026 financial results, reporting revenue of $162.3 million, down 14% year-over-year. Despite the overall revenue decline, Clinical Subscription Revenue saw a significant increase of 30.4% year-over-year. The company highlighted continued sequential growth in its Core+ subscriber base, which increased by 13.9% year-over-year. Management reaffirmed its full-year 2026 financial guidance for both revenue and Adjusted EBITDA, expressing confidence in building momentum into 2027.
Key Highlights
- 1
WW International reported Q2 revenue of $162.3 million, a decrease of 14% year-over-year.
- 2
Clinical Subscription Revenue grew 30.4% year-over-year to $39.9 million.
- 3
Core+ End of Period Subscribers reached 541 thousand, up 13.9% year-over-year, marking the third consecutive quarter of sequential growth.
- 4
Q2 Gross Margin was 70.3%, with Adjusted Gross Margin at 73.6%, remaining near record highs.
- 5
Q2 Net Income was $14.1 million, and Adjusted EBITDA was $39.8 million.
- 6
The company reaffirmed its full-year 2026 revenue guidance of $620 million to $635 million and Adjusted EBITDA guidance of $105 million to $115 million.
Management Comments
Jon Volkmann
We view 2026 as a year of focused transition for Weight Watchers, and our Q2 results reflect that work taking hold across the business. Core+, our high-value Behavioral tier delivering tailored expert coaching and integrated weight health support, posted sequential subscriber growth for the third consecutive quarter, underscoring that members continue to embrace our holistic approach.
Felicia DellaFortuna
We are pleased with the continued momentum in Core+, which saw subscriber count grow 13.9% year-over-year and represents a clear signal that interest in our Behavioral business is stabilizing while our Clinical business continues to grow. End of Period Clinical Subscribers grew 55.7% year-over-year, and the sequential stability we saw in subscribers from Q1 to Q2 2026 reflects a deliberate recalibration of marketing investment following elevated peak season spend. We are reaffirming our full-year 2026 Revenue and Adjusted EBITDA guidance. With a business that remains cash accretive and generated positive operating cash flow in Q2, we have confidence in our ability to continue building momentum into 2027 and beyond.
Informational and educational content only. Not investment advice.